| 000 | 01003 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250517212433.0 | ||
| 264 | 0 | _c20190729 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a1365-2036 | ||
| 024 | 7 |
_a10.1111/apt.14638 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChristensen, B | |
| 245 | 0 | 0 |
_aLetter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _c05 2018 |
||
| 300 |
_a1423-1424 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aCholangitis, Sclerosing |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInflammatory Bowel Diseases |
| 650 | 0 | 4 | _aLiver Diseases |
| 700 | 1 | _aGibson, P R | |
| 700 | 1 | _aRubin, D T | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 47 _gno. 10 _gp. 1423-1424 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/apt.14638 _zAvailable from publisher's website |
| 999 |
_c28307586 _d28307586 |
||